Given Fulcrum Therapeutics' recent announcement to suspend the development of losmapimod and focus on other programs, coupled with its significant price trends, I believe FULC is due for a downturn, making it a suitable candidate for shorting in the current market environment.

I believe that the recent failure of Fulcrum Therapeutics' key trial for losmapimod and the focus on alternative programs indicate potential instability ahead. As a result, I am taking a short position, anticipating further declines in the stock as the market reacts to these developments.